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eukemia cutis (LC) is a rare, cutaneous
infiltration of neoplastic leukemic cells and
correlates strongly to additional sites of extra-
medullary disease.1 LC is a nonspecific term for the
cutaneous manifestations of many subtypes of
leukemia; therefore, the cutaneous morphology
and histopathology of LC varies widely. This distinc-
tion makes it clinically difficult to distinguish from
other nonspecific lesions, especially in the bullous
subtype, which is rare and clinically mimics bug
bites.2 LC usually follows or occurs concomitantly
with the diagnosis of leukemia, and its presence is an
indicator of poor prognosis1 Proper diagnosis of LC is
essential because it can alter a patient’s treatment
course.
CASE PRESENTATION
A 47-year-old African-American man with
recently diagnosed T-cell prolymphocytic leukemia
(T-PLL) presented in the clinic with a widespread
rash for 2 and a half weeks. Nine months before the
dermatology clinic visit, he was admitted to the
hospital with a 2-month history of fatigue, abdominal
discomfort, a white blood cell count of greater than
150K, and generalized lymphadenopathy. Pathology
of an excisional lymph node biopsy found extensive
infiltration by atypical CD21, CD31, CD51, CD71,
CD81, and TCL-11 T cells, indicative of T-PLL.
Fluorescence in situ hybridization analysis found
trisomy 8 and a TCRAD gene rearrangement
involving 14q11. Bone marrow biopsy found 85%
bone marrow involvement. He has since been
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107. E-mail: sarah.siu@jefferson.edu.the diagnosis of leukemia, his medical history was
unremarkable.
On physical examination, there were multiple
skin-colored, violaceous to red-brown papules and
nodules on the entire body including the groin area,
with central vesicles or tiny, crusted erosions
(Fig 1, A). A skin biopsy specimen found marked
spongiosis and edema of the papillary dermis with
perivascular infiltrate of atypical lymphocytes in the
papillary and reticular dermis (Fig 1, B and C ).
Most of the atypical lymphocytes stained posi-
tively for CD3, CD5, CD7, and CD8, consistent with
previous biopsy results of the lymph node, periph-
eral blood, and bone marrow, confirming the pres-
ence of leukemia cells. Thus, a definitive diagnosis
was made for LC secondary to the patient’s known
T-PLL.
DISCUSSION
T-PLL has an aggressive course and is rare,
representing about 2% of mature lymphocytic leu-
kemias in adults older than 30.3 The outcome for
these patients is poor, even without cutaneous
involvement.1 LC is seen in 25% to 30% of cases of
T-PLL.2 Frequency of LC varies widely depending on
the subtype of leukemia and is much higher in
children than in adults (Table I). Skin lesions in LCJAAD Case Reports 2016;2:287-9.
2352-5126
 2016 by the American Academy of Dermatology, Inc. Published
by Elsevier, Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
http://dx.doi.org/10.1016/j.jdcr.2016.05.008
287
Fig 1. A, Multiple, widespread variably sized red-brown papules or nodules with central
vesicles or erosions in a patient with T-PLL. B and C, Within the superficial and deep dermis
there is a perivascular infiltrate of atypical lymphocytes. There is marked spongiosis and edema
of the papillary dermis.
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hemorrhagic papules, nodules, and plaques of
various sizes. Erythematous nodules and papules
are the most common clinical presentation. Legs are
most commonly involved, followed by arms, back,
chest, scalp, and face.2 In T-PLL patients, LC can
manifest as a maculopapular rash, skin nodules, and
occasionally erythroderma.4 Petechial or purpuric
qualities can be noted because of red blood cell
extravasation. Vesiculobullous eruptions are rarely
observed in LC. They were observed in one of 75
Korean patients with LC, 2 of 42 LC cases reviewed
by the Mayo Clinic, and none in 26 patients with
cutaneous myeloid leukemia.5-7 Clinical differential
diagnoses include septic emboli, vasculitis, lym-
phoma cutis, bug bites, and drug eruptions.8
Diagnosis of LC is based on several factors
including morphology of skin infiltration, cytology,
and immunohistochemistry. Most leukemic skin in-
filtrates have a perivascular or periadnexal pattern.
A dense diffuse/interstitial or nodular infiltrate
involving the dermis and subcutis with sparing of
the upper papillary dermis can also be seen.2 Skin
infiltrates in T-PLL are primarily in the upper dermis
with perivascular and periadnexal distribution.4There is no epidermotropism, differentiating it from
mycosis fungoides.2 Combined with the patient’s
history of T-PLL, the histopathologic and immuno-
phenotypic findings in the cutaneous biopsies favor
bullous LC. Thus, other differentials were ruled out,
and a diagnosis of cutaneous involvement by the
patient’s known T-PLL was made.
T prolymphocytes are peripheral T cells that are
CD21, CD31, CD71, and CD521, resulting in similar
immunostaining of cutaneous biopsies of LC1 T-PLL
patients.3 Most T-PLL infiltrates are CD41/CD8, but
13% are CD4/CD81, as seen in this patient.2 T-cell
leukemia-1 (TCL-1) oncogene immunostaining in neo-
plasmsof knownT-cell lineage is also specific toT-PLL,
and high expression is a poor prognostic marker.4 In
T-PLL, the most frequent chromosome abnormality
involves an inversion of chromosome 14 with break-
points at q11 and q32, seen as a TCRAD gene
rearrangement (14q11) in this patient.3 Trisomy 8 is
also seen in two-thirds ofT-PLL cases.9 This patient had
morphologic, phenotypic (positive T-cell markers and
TCL-1 oncogene), and cytogenetic (trisomy 8 and
TCRAD gene rearrangement) findings consistent with
LC related to systemic T-PLL. Bullae formation is
speculated to result from lymphatic obstruction,
Table I. Subtypes of leukemia with skin
involvement
Subtypes
Frequency of skin
involvement
Myeloid/monocytic
Acute myeloid leukemia 10%e15%
Acute myelomonocytic leukemia Up to 50%
Acute monocytic leukemia Up to 50%
Chronic myelogenous leukemia \10%
Chronic myelomonocytic leukemia
(transformation)
\10%
Myelodysplastic syndromes
(transformation)
\10%
Lymphoproliferative disorders
B-cell leukemias/lymphomas
Precursor B-cell acute lympho-
blastic leukemia
Unusual
Chronic lymphocytic leukemia/
small lymphocytic lymphoma
4%e20%
T-cell leukemias/lymphomas
Precursor T-cell acute lympho-
blastic leukemia
Unusual
Adult T-cell leukemia/lymphoma 43%e72%
T-cell prolymphocytic leukemia 25%e30%
Sezary syndrome 20%e70%
Data from Cho-Vega, JH, Medeiros LJ, Prieto VG, Vega F. Leukemia
cutis. Am J Clin Pathol 2008;129(1):130-142.
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injury at the dermoepidermal junction.10
Studies find that 88% of patients who have LC die
within 1 year of diagnosis. The prognosis of bullous
LC is unknown because of limited number of cases.
Because LC is a cutaneous manifestation of a sys-
temic disease, treatment should be aimed at the
systemic disease with intensive chemotherapy and
hematopoietic stem cell transplantation, as well as
local symptoms.2 Currently, intravenous alemtuzu-
mab (anti-CD52) is the best treatment for T-PLL, with
more than 90% response rates and significant
improvement in survival.3
LC related to T-PLL has also been found to
respond well to alemtuzumab therapy. Autologous
or allogeneic stem cell transplant after remission
further prolongs survival, with the latter as apotential cure.4 In this case, although the patient’s
brother is a haplo match, the patient is waiting for his
disease to be further controlled on alemtuzumab and
pentostatin before stem cell transplantation.
T-PLL is a rare and aggressive hematologic malig-
nancy. Although the skin is characteristically
involved, it is not a well-recognized entity in
dermatologic literature, especially the subtype of
bullous LC. LC can often be the manifestation of a
leukemia relapse. A diagnosis of LC generally
portends a poor prognosis and strongly correlates
with additional sites of extramedullary involvement.
Accurate diagnosis has tremendous prognostic
importance and can significantly alter the treatment
regimen of patients. This case report has key clinical
implications in bringing awareness to this disease,
leading to prompt diagnosis and better treatment of
affected patients.REFERENCES
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